BEBT-808 is an orally administered small molecule glucagon-like peptide-1 receptor (GLP-1R) full agonist, intended for the development of diabetes and obesity treatment. GLP-1R agonists effectively lower blood glucose levels and offer cardiovascular protective benefits. They also demonstrate significant weight loss effects with minimal side effects, quickly gaining traction in the global market for weight loss medications. Preclinical animal model studies indicate that BEBT-808 effectively inhibits blood glucose increase in hGLP-1R transgenic mouse OGTT tests. It exhibits higher activity than PF-06882961 and significantly reduces weight in hGLP-1R transgenic mouse high-fat diet-induced obesity models, demonstrating a high level of safety. BEBT-808 is currently in the IND-enabling trial stage.

Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号